(NASDAQ: ILMN) Illumina's forecast annual revenue growth rate of 6.06% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 8.27%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.13%.
Illumina's revenue in 2026 is $4,393,000,000.On average, 23 Wall Street analysts forecast ILMN's revenue for 2026 to be $704,906,700,000, with the lowest ILMN revenue forecast at $672,679,800,000, and the highest ILMN revenue forecast at $732,897,200,000. On average, 23 Wall Street analysts forecast ILMN's revenue for 2027 to be $744,396,000,000, with the lowest ILMN revenue forecast at $701,880,700,000, and the highest ILMN revenue forecast at $782,372,300,000.
In 2028, ILMN is forecast to generate $794,930,200,000 in revenue, with the lowest revenue forecast at $736,831,000,000 and the highest revenue forecast at $869,218,500,000.